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Abstract
Background: Biological therapies have been introduced for the treatment of chronic inflammatory diseases
including rheumatoid arthritis (RA) and Crohn’s disease (CD). The efficacy of biologics differs from patient to
patient. Moreover these therapies are rather expensive, therefore treatment of primary non-responders should be
avoided.
Method: We addressed this issue by combining gene expression profiling and biostatistical approaches. We
performed peripheral blood global gene expression profiling in order to filter the genome for target genes in
cohorts of 20 CD and 19 RA patients. Then RT-quantitative PCR validation was performed, followed by multivariate
analyses of genes in independent cohorts of 20 CD and 15 RA patients, in order to identify sets ofinterrelated
genes that can separate responders from non-responders to the humanized chimeric anti-TNFalpha antibody
infliximab at baseline.
Results: Gene panels separating responders from non-responders were identified using leave-one-out cross-
validation test, and a pool of genes that should be tested on larger cohorts was created in both conditions.
Conclusions: Our data show that peripheral blood gene expression profiles are suitable for determining gene
panels with high discriminatory power to differentiate responders from non-responders in infliximab therapy at
baseline in CD and RA, which could be cross-validated successfully. Biostatistical analysis of peripheral blood gene
expression data leads to the identification of gene panels that can help predict responsiveness of therapy and
support the clinical decision-making process.
Background
Biological therapies targeting tumor necrosis factor alpha
(TNFa) have been introduced for the treatment of
chronic inflammatory diseases including rheumatoid
arthritis (RA) and Crohn’s disease (CD). Up tothe end of
2010 [1], more than two million patients worldwide had
received treatment with anti-TNFa biologic agents, such
as infliximab, adalimumab and etanerceptforconditions
such as RA and CD. The efficacy of these biologics differs
from patient to patient and these agents are rather
expensive, sothey should not be used to treat primary
non-respondersin the long term. In this study, we aimed
at predicting patient response to infliximab, ahumanized
chimeric anti-TNFa antibody, from the genomic
perspective. Infliximab is a genetically constructed immu-
noglobulin G1 murine-humanchimeric monoclonal
antibody binding both to thesoluble subunit and the
membrane-bound precursor of TNFa; and has proven to
be anefficacious treatment for both RA[2] and CD [3].
RA and CD are believed to have a common pathogenetic
background because they can be associated with overlap-
ping biological processes, includingchanged inflammatory
response[4], therefore it is reasonable to expect that over-
lapping gene panels could predict the response to the
same therapy in these two conditions.* Correspondence: nagyl@med.unideb.hu1Department of Biochemistry and Molecular Biology, Debrecen, Egyetemtér,
4028, Hungary
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Gene expression profiling has been successfully used
on tissue samples or blood for the identification of bio-
markers and/or genome classifiers in various disorders,
such as breast cancer [5] and asthma [6]. Peripheral
blood mononuclear cells (PBMCs) contain cells affected
by inflammation, such as circulating monocytes, T-
lymphocytesand B-lymphocytes. Therefore gene expres-
sion patternsof PBMCsmay reflect mechanisms of the
disease, and the challenge is to producepharmacoge-
nomics biomarkers and/or genome classifiersfor clinical
decision making through the development of assays
based on gene panels predicting response to therapies
or disease progression [7]. It would be particularly inter-
esting to know how the PBMCs of patients with CD or
RA respond to the same biological therapy and, if discri-
minating gene panels are available, what the degree of
similarity between such panels is in predicting the out-
come of therapy and disease progression.
There is a clear need for a set of biomarkers and/or gen-
ome classifiers predicting response to infliximab therapy,
underscored by two important problems. First, about 35%
of patients with CD [8] and 20% to 40% of patients with
RA [9,10] fail to respond to this therapy. Second, efficacy
may decline afterswitching to a second TNFa inhibitor
[11]. Therefore, predicting whether a patient will respond
to a particular therapy before starting the first therapeutic
option is clearly an unmet medical need. This predictive
ability would have a strong effect on the use of these medi-
cations, and could lower healthcare costs and give the
patient the opportunity to receive ‘personalized’ therapy.
Biomarkers or sets of biomarkers and/or genome classi-
fiers predicting response to therapy by using the least inva-
sive peripheral blood sampling have clear advantages [12].
The response to infliximab therapy has been examined
in CD by using colon biopsy samples [13] and in RA using
blood [14,15] as well as synovial biopsy [16]. A comparison
of the response from the genomic perspective in both con-
ditions in PBMCs has never been documented.
In the present study, we performed PBMC global gene
expression profiling for filtering the genome for target
genes on one cohort of patients with CD and one cohort
with RA. Wethen performed RT-quantitative PCR gene
expression in PBMCs on independent cohorts,followed by
multivariate analyses to identify interrelated gene sets that
can differentiate responders from non-responders to
infliximab therapy in an independent cohort. Compared to
studies in which single genes differentiating between
responders and non-responders are the focus, our analysis
put an emphasis on identifying interrelated gene panels
showing differences between the above-mentioned groups.
Our results demonstrate that peripheral blood gene
expression profiles are suitable for determining panels of
interrelated genes with high discriminatory power,as
shown by cross-validation analyses that can differentiate
responders from non-responders to infliximab therapy
at baseline in cohorts of patients with CD and with RA.
We found that distinct, non-overlapping panels of inter-
related genes can be used to predict the responder sta-
tus in these conditions.
Methods
Patient samples
The Institutional Review Board of University of Debre-
cen Medical and Health Science Center approved the
clinical protocol and study, which were in compliance
with the Helsinki Declaration. Signed informed consent
was obtained from all individuals providing blood
sample.
In total, 40 Caucasian patients with CD (16 females, 24
males) diagnosed by clinicians; and 34 Caucasian patients
(28 females, 6 males) who met the 2010 European League
Against Rheumatism/American College of Rheumatology
(ACR) classification criteria[17] for RA were included in
the study; all of whom had active disease at the time blood
was drawn. Regarding the study design, 20 patients with
CD and 19 with RA were included in the first test cohort
for microarray experimentsampling at baseline and week
2. For the validation cohort, samples from 20patients with
CDand 15with RAat baseline were included in the RT-
quantitative PCR experiments. The schematic outline of
our study design is given in Figure 1.
All blood samples were obtained after the partici-
pantsfasted overnightfor 12 hours locally between 8:00
am and 9:00 ambefore the first admission of infliximab
at week 0 (baseline) and the second at week 2; and were
processed within one hour after sample collection.
Medicationsthatremained unchanged during the study
and patient co-morbiditiesare shown in Tables 1 and 2.
Co-medication was given after blood was taken.
Clinical parameters, including Crohn’s disease activity
score (CDAI), C-reactive protein (CRP), hemoglobin, leu-
kocyte and neutrophil counts in CD; and Disease Activity
Score (DAS28), Health Assessment Questionnaire
(HAQ), CRP and disease-modifying anti-rheumatic drugs
(DMARDs) in RA were assessed at the time of the first
infliximab infusion (baseline), at the second infusion
(week 2), and at week 6 or 14 when the responder status-
was determined based on clinicians’ assessment.
The inclusion criteria in RA were fulfillment of the
2010 European League Against Rheumatism/ACR classi-
fication criteria; age between 20 and 60 years; failure to
respond to at least two DMARDs; active disease (DAS28
>3.2);and anti-TNFa therapy-naive patients or previous
anti-TNFa use at least 3 months prior to blood sampling.
Prednisone therapy ≤10 mg per day was allowed provided
that the dosage had been stable for at least 2 months
before entryand non-steroidal anti-inflammatory drugs
were allowed in doses stable for at least 1 month before
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baseline.Patients were on maximal-tolerable methotrex-
ate treatment (5 to 30 mg per week), which had to be
stable for at least 4 weeks before baseline.Exclusion cri-
teria were pregnancy or breastfeeding; current or recent
cancer; active infectious disease; a history of an acute
inflammatory joint disease of different origin; and
smoking.
Inclusion criteria in CD were clinically diagnosed CD;
age between 20 and 60 years; CDAI >250; anti-TNFa
therapy-naive patients; and prednisolone therapy with a
dosage of less than 10 mg/day.Exclusion criteria were
pregnancy or breastfeeding; current or recent cancer;
active infectious disease; and smoking.
Responder status was determined by a CDAI decrease of
100 points compared to baseline in CD at week 6; and by
ACR categories at week 14 in RA (ACR0% and ACR20%
improvement represent the non-responder; ACR50% and
ACR70% represent the responderstatus).
Figure 1 Schematic outline of the study design. CD,Crohn’s disease;NR, non-responder; R, responder; RA, rheumatoid arthritis.
Table 1 Summary of the clinical parameters of patients with Crohn’s disease
Responders Non-responders Responders Non-responders
Test cohort Validation cohort Difference
At baseline 14 6 13 7
Gender (male/female) 8/6 4/3 8/5 4/4
Age (years) 36.2±14.6 36±15.4 26.8±8.7 30.2±5.1 Non-significant
CDAI 319.6±41.3 351.5±33.1 338.3±61.7 370.7±48.1 Non-significant
CRP (mg/ml) 22.7±20.2 13.5±28.9 27.2±36.2 16.5±11.6 Non-significant
Hemoglobin (g/l) 125.1±17.6 120.6±27.6 130±17.9 127±12 Non-significant
Leukocytes(g/l) 9±3.3 8±3.1 7.5±2.3 9.2±2.8 Non-significant
Neutrophils (%) 70±8.9 74.5±8.9 74±8.1 72.8±5.7 Non-significant
CDAI, Crohn’s disease activity index; CRP, C-reactive protein. Data are shown as mean ±SD.
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Peripheral blood mononuclear cell and RNA isolation
Venous peripheral blood samples were collected (10 ml) in
Venous Blood Vacuum Collection Tubes containing
EDTA (BD Vacutainer K2EDTA, Becton Dickinson, New
Jersey, United States). PBMCs were separated by Ficoll
gradient centrifugation. Total RNA was extracted from
PBMCs using Trizol reagent (Invitrogen, Carlsbad, Cali-
fornia, United States), according to the manufacturer’s
protocol. RNA quality was checked onan Agilent Bioanaly-
zer 2100 (Agilent Technologies, Santa Clara, California,
United States); all samples had a 28S/18S ratio between
1.5 and 2.0 and the RNA Integrity Number was between
9 and 10. Quantity was determined usingNanoDrop
(Thermo Scientific, Waltham, Massachusetts, United
States).
Microarray
AffymetrixGeneChip Human Gene 1.0 ST array (Affyme-
trix, Santa Clara, California, United States) was used to
analyzethe global expression pattern of 28,869 well-anno-
tated genes. Ambion WT Expression Kit (Applied Biosys-
tems, Foster City, California, United States) and GeneChip
WT Terminal Labeling and Control Kit (Affymetrix) were
used for amplifying and labeling 250 ng of RNA samples.
Samples were hybridized at 45°C for 16 hours and then
standard washing protocol was performed using GeneChip
Fluidics Station 450 and the arrays were scanned on Gene-
Chip Scanner 7G (Affymetrix).
Univariate data analysis
Microarray data (Gene Expression Omnibus accession
number: [GEO:42296]) were analyzed with Genespring
GX10 (Agilent Technologies). Affymetrix data files were
imported using the robust multi-array analysis algorithm
and median normalization was performed, then genes
with low expression levels were filtered out removing the
lowest 20% based on raw intensity values.Differentially
expressed genes between responders versus non-respon-
ders and baseline versus week 2 conditions were identified
using Mann-Whitney U test with a fold-change cut off 1.5.
RT-quantitative PCR measurements
Gene expression data were obtained using TaqMan Low-
Density Array (Life Technologies, Carlsbad, California,
United States). Our custom-designed TaqMan LowDensity
Array card allows for two samples to be run in parallel
against 96 TaqMan gene expression assays. Based on our
microarray experiment and the relevant literature, 91
genes were chosen; the remaining fivegenes were house-
keeping genes for normalization (ACTB, GAPDH, HPRT1,
PPIA andRPLP0). cDNA was generated with High Capa-
city cDNA Reverse Transcription Kit (Life Technologies)
according to manufacturer’s protocol. RT-quantitative
PCR amplification was performed using an ABI Prism
7900HT instrument (Life Technologies).Relative gene
expression levels were calculated by a comparative Ct
method that results in normalizing to PPIA(Peptidylproly-
lIsomerase A (Cyclophilin A))expression for each sample.
Multivariate data analysis: canonical variates analysis or
linear discriminant analysis
Separation between predefined groups of objects is best
revealed by canonical variates analysis (CVA). This
method is the extension of linear discriminant analysis
(LDA), and the two terms are used equivalently in this
study. CVA was used to determine whether the groups of
respondersand non-responders are separable in the multi-
dimensional space spanned by the genetic variables, and if
so, which gene subsets have the best discriminatory
power. The results of CVA are the so-called canonical
scores obtained from the canonical functions derived
through eigenanalysis, which serve as coordinates of
observations in the canonical space. A more detailed
description about CVA is included in Additional file 1.
A receiver operating characteristic (ROC) curve shows
the performance of a binary classifier. The curve provides
a complete sensitivity and specificity report, where each
point represents a sensitivity-specificity pair at various cut
points. The area under the ROC curve (AUC) is a diagnos-
tic measure indicating how a parameter can distinguish
between two groups (responder and non-responder).
Table 2 Summary of the clinical parameters of patients with rheumatoid arthritis
Responders Non- or moderate responders Responders Non- or moderate responders
Test cohort Validation cohort Difference
At baseline 6 13 4 11
Gender (male/female) 1/5 2/11 0/4 3/8
Age (years) 44.3±9.3 47±10.7 54±17 56.2±6.8 Non-significant
DAS28 5.6±0.3 5.2±0.7 5.2±0.06 5.4±0.5 Non-significant
HAQ 1.2±0.7 2±0.6 1.5±1.1 1.9±0.7 Non-significant
CRP (mg/ml) 16.8±18.3 28.3±23.8 18.9±18.3 9.5±10.3 Non-significant
DMARDs 2.8±0.9 2.6±0.7 3±0.8 2.7±1.4 Non-significant
CRP, C-reactive protein;DAS28, Disease Activity Score; HAQ, Health Assessment Questionnaire; DMARD, disease-modifying anti-rheumatic drug (methotrexate).
Data are shown as mean±SD.
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Automated gene panel generation
LDA [18]and ROC analyses were performed using R
software (R Development Core Team [19]) with
packages MASS[20] and ROCR[21], respectively, to
automatically generate gene panels according to thefol-
lowing algorithm (Figure 2):
1. The set of ‘genes in model’ is created. This set
represents the genes that were not yet removed perma-
nently. Initially, this set contains all genes. A set of
genes with ‘already tested genes’ is also created. Initially,
this set is empty.
2. The F-value, that is, the ratio of between-group
variability and within-group variability, is calculatedfor
each gene.
3. The classifier algorithm (LDA) is run using the set
of ‘genes in model’. The accuracy percentage value is
recorded as the’best accuracy value’.
4. The set of ‘selectable genes’ is defined as:’selectable
genes’= ‘genes in model’ minus ‘already tested genes’. If
the group of ‘selectable genes’ is not empty, the algo-
rithm is continued in step 5. Otherwise, thealgorithm
skips to step 7.
5. A gene is selected from the set of ‘selectable genes’
(to avoid performing the same calculation more than
once as well as to terminate the algorithm) according to
the following models:
a. Randomly with equal probabilities (uniform
model);
b. Randomly with a probability that is inversely pro-
portional to their F-value (F_propmodel);
c. Genes with the lowest F-values (min F model).
6. In either case, the selected gene is temporarily
removed from the set of ‘genes in model’.The advantage
of using stochastic models instead of min F model is
that theycan provide bettersegregation of patient groups.
Uniform and F_prop models represent stochastic algo-
rithms whilethe min F model is deterministic.
7. The classifier is run using the (temporarily reduced)
set of ‘genes in model’.
a. If the accuracy percentage value becomes lower,
the selected gene isreinserted into the set of ‘genes
Figure 2 Schematic flowchart of automatic gene panel generation. LDA, linear discriminant analysis.
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in model’ and added to the set of ‘already tested
genes’.
b. If the accuracy percentage value is at least as good
as the ‘best accuracy value’, theselected gene is per-
manently removed from ‘genes in model’ and the set
of ‘already tested genes’is emptied. The ‘best accu-
racy value’ is overwritten with the calculated accu-
racy value.The algorithm returns to step 4.
8. The algorithm ends. The outputs include the set of
‘genes in model’ and ‘best accuracy value’.
Results
Clinical characteristics
In CD, we identified 14 respondersand 6 non-responders
in the test cohort; and 13 responders and 7 non-respon-
ders in the validation cohort. There were no significant
differences regarding age, CDAI, CRP, hemoglobin, leuko-
cytes or neutrophils between the responders and non-
responders (Table 1).
In RA, we used a binary outcome variable to assess clini-
cal responder status: patients with ACR0% or ACR20%
scores were classified as non-responders; and patients with
ACR50% or ACR70% scores were classified as responders.
We identified 6 responders and 13 non- or moderate-
responders in the test cohort; and 4 responders and 11
non- or moderate-responders in the validation cohort.
There were no significant differences regarding age,
DAS28, HAQ, CRP, rheumatoid factor, anti-cyclic citrulli-
nated peptide (anti-CCP)antibody status or DMARDs
between respondersand non-responders (Table 2).
Global gene expression analyses identify differentially
expressed genes between responders and non-
responders in Crohn’s disease and rheumatoid arthritis
In CD, global gene expression analysis resulted in a list of
48 genes through filtering steps based on expression levels,
fold-change cut-off at 1.5 and statistical significant ana-
lyses differentiating responders from non-responders at
baseline. Analysis of samples obtained at week 2 identified
12differentially expressed genes with statistically signifi-
cant differences between respondersand non-responders.
Among these genes,ABCC4, BMP6 and THEM5were sig-
nificantly changing at baseline as well; others were new
findings at week 2, such as CA2, CADM2, GPR34, IL1RL1,
MMD, PRDM1, RAD23A and SLC7A5 (Table S1a in Addi-
tional file 1).
In RA, analysis of baseline samples resulted in a list of
30 genes showing statistically significant differences
between responders and non-responders. From this list,
some of the genes such as RGS1EPSTI1, IFI44, IFIT1,
IFIT2, IFIT3, RFC1 and RSAD2 were also significantly
changed at week 2 as well, while others showed changes at
week 2 only, such as ELOVL7, FCGR3A, GPAM, MICA
and PF4(Table S1b in Additional file 1).There is no over-
lap between the final gene panels of CD and RA regarding
the responder versus non-respondercomparison.
Comparing baseline and week 2 samples resulted in
three genes (AQP9, IGJ and TNFAIP6) with statistically
significant differences. These genes correlate with the
effects of the therapy and disease progression over time.
There is no overlap between the final gene panels of
CD and RA regarding the responder versus non-respon-
der comparison, but AQP9 and TNFAIP6 overlapped
regarding the baseline versus week 2 comparisons,
which account for the effects of therapy.
Biostatisticalanalysis of RT-quantitative PCR gene
expression data
Genes that showed differential expression between
responder and non-responder in the microarray experi-
ment were validated on a biologically independent
patient cohort in both conditions, using an RT-quantita-
tive PCR method.
The RT-quantitative PCR data were analyzed with the
LDA algorithm and lists of gene panels showing a per-
fect segregation between responder and non-responder-
werecreated. Leave-one-out cross-validation was used to
strengthen the statistical power of the lists.ROC-AUC
analyses were visualized to show the true positive and
false positive rates of gene panels with the bestcross-
validation rates (Figure 3).
Based on the accuracy of cross-validation and the sen-
sitivity of these gene panels, the threelists with the best
discriminatory power were chosen for visualization in
both conditions to show how responder and non-
responder patients are segregated (Figure 4). The lists
with the best discriminatory power include BTN3A2,
CD300E, ENDOD1, FMN1, KAT2B, ODC1, PBX1and
UBE2H in CD,and IFI44, MX1, ORA2A9P, PF4and
RFC1 in RA.
Genes fromgene panels with cross-validation accuracy
over 80% were ranked based on the number of times
they appeared in such gene panels to show the most
important genes in differentiating respondersfrom non-
responders (Table 3).
Discussion
Predicting whether a patient responds to a specific bio-
logical therapy could have significant health and eco-
nomic benefits, but a prediction based only on clinical
parameters and disease activity scores does not yield the
required efficacy. The detection of gene panels including
genome classifiers discriminating between future respon-
ders and non-responders through the minimally invasive
peripheral blood sampling either in CD or RA is clearly
a yet unmet medical and diagnostic need. The most
common approach to this problem is to identify
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individual genes showing statistically significant differ-
ences between responders and non-responders [10].
We combined these two approaches by performing glo-
bal gene expression analyses in a test cohort to identify a
panel of genes that later could be validated in an indepen-
dent cohort. Our more sensitive method yielded several
genes relevant to CD and RA based on the literature.
In CD, examples include CYP1B1 that has been marked
as an inflammatory bowel disease marker compared to
healthy controls in peripheral blood gene expression pro-
files [4]; RNASE2 was significantly reduced in patients
with inflammatory bowel disease compared to healthy
controls in peripheral polymorphonuclear leukocytes[22],
as was FCGR1A, an inflammation-related gene thatis up-
regulated in PBMCs of patients withulcerative colitis and
CD [23]. A single nucleotide polymorphism of IL18R1
[24] or PRDM1[25]was associated with CD.
As regulation of gene activity of interferon response dur-
ing infliximab therapy in RA is associated with the
treatment response based on whole blood gene expression
profiling, it was not surprising to detect numerous genes
related to the interferonpathways that had been previously
investigated [10] such as IFI44, IFI44L, IFIT1, IFIT2 and
IRF2. PTGS2also discriminated patients with RA from
healthy controls in PBMCs at the gene expression level
[4]; and the genetic polymorphism of RFC1 modifies
methotrexate transport and metabolic effects and through
that can influence response to treatment[26].
The RT-quantitative PCR technique was used to mea-
sure the expression levels of our pre-selected genes
from the microarray analysis on biologically independent
patient cohorts in both conditions; and LDA was applied
to identify gene panels with the highest discriminatory
power. Univariate analyses may disregard potential
interactions among genes,but LDA can reveal underlying
differences by using genes simultaneously as a gene
panel, providing perfect segregation in the multidimen-
sional space.
Figure 3 Receiver operator characteristic-area under the curveanalyses. The ratio between true and false positive discovery rates are shown
in (A) Crohn’s disease and (B) rheumatoid arthritis with the gene panels demonstrating an accuracy in differentiating between responder and
non-responder patients of over 90%. CV stands for the success of cross-validation.
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The high number of gene panels with 100% segrega-
tion and gene panels with accuracy of over 90% after
cross-validation show that it is likely to find such panels
when testing on larger cohorts. This could also mean
that, regarding the development of a diagnostic assay
predicting response to infliximab therapy in RA and CD,
using a gene set containing 20 to 24 genes seems to be
more reasonable than selecting individual gene lists con-
sisting of typically 5 to 8 genes, provided that an LDA-
based approach is used.
Figure 4 Biostatistical analysis of gene expression data. Three gene lists scored by linear discriminant analysisin (A) Crohn’s disease and (B)
rheumatoid arthritis. Red bars represent non-responders; blue bars represent responders. The larger the distance between the groups and the
smaller the overlap between samples, the higher the power of separation of the gene list.
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To provide compact gene panels resulting in a perfect
segregation between responders and non-responders, as
well as a success rate of over 90% after cross-validation, we
detected and visualized these prominent gene panels - in
which many of the genes overlapped in the different groups.
Understanding the limitation of our study regarding
the sizes of the cohorts, we created pool of genes which
appeared the most times in the best performing gene panels
to let other research groups test these in larger cohorts. A
strategy combining such data sets and cohorts worldwide
would have the highest chance of success in providing the
community with validated gene lists usable in any cohorts.
This research could lead us to the diagnostic use of such
gene arrays in predicting the response to infliximab ther-
apy in CD and RA. The final conclusion of our study was
that, althoughan ultimate gene panel might have been
expected to be found, there is no such panel but instead a
pool of genes with high statistical power that could be
tested in further cohorts using LDA.
Conclusions
In this work, we provided twopieces of proof of concept
to show that peripheral blood gene expression profiles
are suitable for determining gene panels with the high-
est discriminatory power that can differentiate respon-
ders from non-responders at baseline in CD and RA
patient cohorts and can also be validated in independent
cohorts; and despite the similar pathogenetic back-
ground of CD and RA, distinct, non-overlapping gene
panels predict the responder status in these conditions.
Such gene panels couldcontribute to the solution of
unmet needs in clinical decision making by determining
in advance whether a patient willrespond to a specific
and expensive biologic therapy by analyzing the gene
expression patterns of the least invasively obtained per-
ipheral blood samples, therefore prevent the patient
from receiving an inefficient therapy and then cycling to
an efficient one that could not then achieve the same
efficacy as it would have done if used in the first place.
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Table 3 List of genes of gene panels with cross-validation
accuracy over 80%
Crohn’s disease Rheumatoid arthritis
Number Gene name Number Gene name
59 UBE2H 26 IFI44
38 ODC1 19 PF4
33 CD300E 18 RAVER2
33 PCYT1B 16 IFIT1
31 AIDA 14 IFIT3
31 RIOK3 12 APOBEC3A
30 PBX1 12 ELOVL7
25 ARHGEF12 12 MICA
24 MMD 12 OR2A9P
23 BMP6 11 IFI44L
23 WARS 11 MME
22 ENDOD1 10 CCL4
21 CYP1B1 10 RGS1
21 GCLC 9 IRF7
20 BTN3A2 8 EPSTI1
20 RNF11 7 MX1
19 CADM2 6 DHRS9
19 MAP1LC3B 5 RFC1
17 KAT2B 5 SERPING1
16 IL18R1 3 IFI6
15 FMN1 2 IFI35
12 CA2 1 IFITM1
12 IL1RL1 0 GZMB
Order of genes based on the number of times included in gene panels with
cross-validation accuracy over 80%. Number means the number of times the
gene was included in such gene panels.
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